de Freitas Dias B, Robinson C, Villar-Martinez M, Ashina S, Goadsby P
Pain Ther. 2024; 14(1):1-19.
PMID: 39489854
PMC: 11751248.
DOI: 10.1007/s40122-024-00674-7.
Svane N, Ballgren F, Ginosyan A, Kristensen M, Brodin B, Loryan I
J Headache Pain. 2024; 25(1):187.
PMID: 39478486
PMC: 11523665.
DOI: 10.1186/s10194-024-01894-0.
Kogelman L, Falkenberg K, Ottosson F, Ernst M, Russo F, Stentoft-Hansen V
Sci Rep. 2023; 13(1):12395.
PMID: 37524744
PMC: 10390468.
DOI: 10.1038/s41598-023-38904-1.
Li C, Dai W, Miao S, Xie W, Yu S
Front Neurol. 2023; 14:1118929.
PMID: 36937526
PMC: 10017752.
DOI: 10.3389/fneur.2023.1118929.
Gawde P, Shah H, Patel H, Bharathi K, Patel N, Sethi Y
Cureus. 2023; 15(2):e34553.
PMID: 36879707
PMC: 9985459.
DOI: 10.7759/cureus.34553.
Arc-Mediated Synaptic Plasticity Regulates Cognitive Function in a Migraine Mouse Model.
Hu L, Gong Q, Zhou Y, Wang Y, Qiu T, Fang Y
Brain Sci. 2023; 13(2).
PMID: 36831874
PMC: 9954307.
DOI: 10.3390/brainsci13020331.
European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure.
Sacco S, Lampl C, Amin F, Braschinsky M, Deligianni C, Uluduz D
J Headache Pain. 2022; 23(1):133.
PMID: 36224519
PMC: 9555163.
DOI: 10.1186/s10194-022-01502-z.
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain.
Lipton R, Dodick D, Goadsby P, Burstein R, Adams A, Lai J
Neurology. 2022; 99(17):e1905-e1915.
PMID: 35977836
PMC: 9620813.
DOI: 10.1212/WNL.0000000000201031.
New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach.
Simonetta I, Riolo R, Todaro F, Tuttolomondo A
Int J Mol Sci. 2022; 23(6).
PMID: 35328439
PMC: 8955051.
DOI: 10.3390/ijms23063018.
Pharmacogenetics in Primary Headache Disorders.
Belyaeva I, Subbotina A, Eremenko I, Tarasov V, Chubarev V, Schioth H
Front Pharmacol. 2022; 12:820214.
PMID: 35222013
PMC: 8866828.
DOI: 10.3389/fphar.2021.820214.
A prolactin-dependent sexually dimorphic mechanism of migraine chronification.
Ikegami D, Navratilova E, Yue X, Moutal A, Kopruszinski C, Khanna R
Cephalalgia. 2021; 42(3):197-208.
PMID: 34510920
PMC: 11668309.
DOI: 10.1177/03331024211039813.
Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor.
Blumenfeld A, Durham P, Feoktistov A, Hay D, Russo A, Turner I
Neurol Ther. 2021; 10(2):469-497.
PMID: 34076848
PMC: 8571459.
DOI: 10.1007/s40120-021-00250-7.
Medication overuse and drug addiction: a narrative review from addiction perspective.
Takahashi T, Ornello R, Quatrosi G, Torrente A, Albanese M, Vigneri S
J Headache Pain. 2021; 22(1):32.
PMID: 33910499
PMC: 8080402.
DOI: 10.1186/s10194-021-01224-8.
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
Blumenfeld A, Goadsby P, Dodick D, Hutchinson S, Liu C, Finnegan M
Headache. 2021; 61(3):422-429.
PMID: 33749826
PMC: 8252782.
DOI: 10.1111/head.14089.
Organic Cation Transporter (OCT/OCTN) Expression at Brain Barrier Sites: Focus on CNS Drug Delivery.
Betterton R, Davis T, Ronaldson P
Handb Exp Pharmacol. 2021; 266:301-328.
PMID: 33674914
PMC: 8603467.
DOI: 10.1007/164_2021_448.
Association between response to triptans and response to erenumab: real-life data.
Frattale I, Caponnetto V, Casalena A, Assetta M, Maddestra M, Marzoli F
J Headache Pain. 2021; 22(1):1.
PMID: 33407070
PMC: 7789681.
DOI: 10.1186/s10194-020-01213-3.
The Potentials of Uncariae Ramulus Cum Uncis for the Treatment of Migraine: Targeting CGRP in the Trigeminovascular System.
Chong C, Zhong Z, Vong C, Wang S, Lu J, Zhong H
Curr Neuropharmacol. 2020; 19(7):1090-1100.
PMID: 33121411
PMC: 8686315.
DOI: 10.2174/1570159X18666201029150937.
Novel Analgesics with Peripheral Targets.
Ciotu C, Fischer M
Neurotherapeutics. 2020; 17(3):784-825.
PMID: 33063247
PMC: 7609673.
DOI: 10.1007/s13311-020-00937-z.
Lasmiditan mechanism of action - review of a selective 5-HT agonist.
Clemow D, Johnson K, Hochstetler H, Ossipov M, Hake A, Blumenfeld A
J Headache Pain. 2020; 21(1):71.
PMID: 32522164
PMC: 7288483.
DOI: 10.1186/s10194-020-01132-3.
A Pre-Existing Myogenic Temporomandibular Disorder Increases Trigeminal Calcitonin Gene-Related Peptide and Enhances Nitroglycerin-Induced Hypersensitivity in Mice.
Shu H, Liu S, Tang Y, Schmidt B, Dolan J, Bellinger L
Int J Mol Sci. 2020; 21(11).
PMID: 32516986
PMC: 7313473.
DOI: 10.3390/ijms21114049.